Berkley Life Sciences Offers LS Prime Corporate Lifeline - a FCPA Insurance Expense Coverage for Life Science Companies
Berkley Life Sciences has introduced Corporate Lifeline, an essential new coverage for life science companies seeking to effectively address increased government scrutiny of company practices under the Foreign Corrupt Practices Act.
In 2009 the Criminal Division of the US Department of Justice warned that “in the months and years ahead,” the Department would focus on “the application of the Foreign Corrupt Practices Act to the pharmaceutical industry.” Since that time the DOJ, and the Securities and Exchange Commission on the civil side, have kept this promise. Numerous life science companies and their executives have come under the enforcement microscope, requiring them to incur significant costs to respond to FCPA governmental inquiries into both their business activities and recordkeeping practices. These costs often are incurred even where no prosecution has been initiated, or claim against a company made.
Integrated with Berkley Life Sciences’ comprehensive and forward-thinking LS Prime liability policy, Corporate Lifeline addresses the pre-claim and other expenses associated with an FCPA inquiry or investigation. These costs are not addressed by the typical general liability policy issued to life science company clients, or even by many directors and officers policies.
Losses addressed by Corporate Lifeline include not only the costs to defend against an FCPA proceeding, but also pre-suit response costs, such as certain pre-suit legal advisory expenses, and even certain self-reporting costs. The expenses incurred to seek the release of an executive or employee from foreign confinement are also part of the coverage.
Commenting on this new coverage, Jill Wadlund, President of Berkley Life Sciences, stated: “Pharmaceutical, medical device and biotech companies confront unique FCPA risks, chiefly due to significant levels of government interaction and approval during nearly every stage of business. Of additional significance is that the definition of a government official under the FCPA could include health care providers employed by state owned entities such as government run hospitals in foreign countries. Corporate Lifeline has been carefully tailored to assist customers when they need help the most — when first contacted by the government, or when internal inquiry suggests that self-reporting is the best option to avoid or mitigate potential hefty civil and criminal penalties and reputational damage associated with an FCPA violation.”
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance